Aeglea BioTherapeutics, Inc. develops human enzyme therapies for rare metabolic diseases, with a focus on their lead product candidate pegzilarginase, a recombinant human Arginase 1 in Phase III PEACE trial. They also have a Phase I/II clinical trial for AGLE-177 for the treatment of homocystinuria and a preclinical pipeline program for AGLE-325 for the treatment of cystinuria. Aeglea BioTherapeutics, Inc. was founded in 2013 and is located in Austin, Texas.